Literature DB >> 19932947

Endovenous therapy for the treatment of congenital venous malformations.

Onur Berber1, Peter Holt, Robert Hinchliffe, Matthew Thompson, Ian Loftus.   

Abstract

The treatment of a congenital venous malformation using endovenous radiofrequency ablation in a patient is described. The patient initially underwent two treatments of foam sclerotherapy with moderate success. Later the main feeding vessel of the venous malformation became evident on examination with venous duplex and was identified as the great saphenous vein. At this point, endovenous radiofrequency ablation was used to ablate the feeding vessel and successfully treat the lesion. The procedure proceeded without complications, and the patient made a good recovery. It is recommended that patients presenting with such malformations be considered for endovenous therapy as early as possible. Copyright (c) 2010 American Society of Echocardiography. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19932947     DOI: 10.1016/j.avsg.2009.08.008

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  3 in total

1.  Non-invasive magnetic resonance-guided high intensity focused ultrasound ablation of a vascular malformation in the lower extremity: a case report.

Authors:  Johanna M M van Breugel; Robbert J Nijenhuis; Mario G Ries; Raechel J Toorop; Evert-Jan P A Vonken; Joost W Wijlemans; Maurice A A J van den Bosch
Journal:  J Ther Ultrasound       Date:  2015-12-30

2.  [The marginal vein-Still a rare entity: case series of 16 patients].

Authors:  D Liebetrau; R Marnoto; Y Goßlau; S Zerwes; Franz Stangl; W A Wohlgemuth; A Hyhlik-Dürr
Journal:  Chirurgie (Heidelb)       Date:  2022-06-29

3.  Comparison between absolute ethanol and bleomycin for the treatment of venous malformation in children.

Authors:  Jing Zhang; Hai-Bo Li; Shao-Yi Zhou; Kun-Shan Chen; Chuan-Qiang Niu; Xiao-Yun Tan; Yi-Zhou Jiang; Que-Qing Lin
Journal:  Exp Ther Med       Date:  2013-06-05       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.